Department of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan.
J Neurooncol. 2021 Aug;154(1):93-100. doi: 10.1007/s11060-021-03803-w. Epub 2021 Jul 9.
Vestibular schwannomas (VSs) are comparatively rare in younger patients, and stereotactic radiosurgery (SRS) outcome data are limited. We aimed to evaluate long-term SRS outcomes concerning sporadic VSs in patients aged ≤ 40 years.
Of 383 patients with VS who had undergone SRS at our institution between 1990 and 2017, we retrospectively compared younger and older patients' tumor control and radiation-induced complication rates using case-control propensity score (PS) matching.
The mean follow-up was 83 and 92 months in older and younger patients, respectively. Compared with older patients, younger patients were more likely to have a history of resection (20% vs. 39%, p = 0.006) and be treated with higher marginal doses (median, 12 Gy vs. 14 Gy; p = 0.014). Cumulative 5- and 10-year tumor control rates were higher in older patients (97.7% and 93.9%, respectively) than in younger patients (90.2% and 85.4%, respectively, p = 0.024). After PS matching, younger patients' cumulative tumor control rates (93.6%, 85.4%, and 85.4% at 5, 10, and 15 years, respectively) were similar to those of older patients (p = 0.411). No significant between-cohort differences in hearing preservation rates or other cranial nerve complications were observed. Two younger patients had malignant tumors several years post-SRS, with one patient having confirmed histological transformation.
SRS is equally effective for younger and older patients. Complications other than hearing deterioration are uncommon. However, malignant transformation is possible, and long-term post-SRS surveillance MRI is important. These data are useful for decision-making involving young adults with VSs.
前庭神经鞘瘤(VS)在年轻患者中相对少见,立体定向放射外科(SRS)的结果数据有限。我们旨在评估年龄≤40 岁的散发性 VS 患者接受 SRS 治疗的长期 SRS 结果。
在我们机构,1990 年至 2017 年间,383 名 VS 患者接受了 SRS,我们回顾性地通过病例对照倾向评分(PS)匹配比较了年轻患者和老年患者的肿瘤控制率和放射性并发症发生率。
老年患者和年轻患者的平均随访时间分别为 83 和 92 个月。与老年患者相比,年轻患者更有可能有手术史(20%比 39%,p=0.006)和接受更高的边缘剂量(中位数,12Gy 比 14Gy;p=0.014)。老年患者的累积 5 年和 10 年肿瘤控制率更高(分别为 97.7%和 93.9%),而年轻患者的肿瘤控制率分别为 90.2%和 85.4%(p=0.024)。经过 PS 匹配后,年轻患者的累积肿瘤控制率(分别为 5、10 和 15 年的 93.6%、85.4%和 85.4%)与老年患者相似(p=0.411)。两组间听力保存率或其他颅神经并发症无显著差异。两名年轻患者在 SRS 后几年发生恶性肿瘤,其中一名患者经组织学证实发生了转化。
SRS 对年轻患者和老年患者同样有效。除听力下降外,并发症并不常见。然而,恶性转化是可能的,SRS 后长期的 MRI 随访很重要。这些数据有助于年轻 VS 患者的决策。